Physician profile
Stephen Dickey
NPI 1407863939
$9,321.33
in general payments reported to CMS, 2019-2025
50 companies · $858 in 2025
The $858 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,695 · 2020: $697 · 2021: $1,171 · 2022: $1,577 · 2023: $1,518 · 2024: $1,805 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,622 · Travel and Lodging: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,622.43 |
| Travel and Lodging | $559.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,142.52 | 2019-2025 | Krystexxa, Evenity, Repatha |
| Medtronic, INC. | $1,117.74 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Btg International INC. | $979.60 | 2019 | |
| Abbvie INC. | $836.10 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $737.31 | 2019-2025 | Rexulti |
| Lilly USA, LLC | $516.38 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $367.64 | 2019-2024 | Trelegy Ellipta, Arexvy, Rotarix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.09 | 2020-2025 | Jardiance |
| Horizon Therapeutics Plc | $327.98 | 2019-2023 | Krystexxa |
| Astellas Pharma US INC | $230.94 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $188.46 | 2019-2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $187.91 | 2021-2025 | |
| Pfizer INC. | $181.96 | 2019-2024 | |
| Allergan, INC. | $170.88 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $166.01 | 2019-2025 | Airsupra, Farxiga |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Dickey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.